These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10975963)

  • 21. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
    Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
    AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.
    Tantisiriwat W; Tebas P; Clifford DB; Powderly WG; Fichtenbaum CJ
    Clin Infect Dis; 1999 May; 28(5):1152-4. PubMed ID: 10452651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
    Bart PA; Rizzardi GP; Tambussi G; Chave JP; Chapuis AG; Graziosi C; Corpataux JM; Halkic N; Meuwly JY; Munoz M; Meylan P; Spreen W; McDade H; Yerly S; Perrin L; Lazzarin A; Pantaleo G
    AIDS; 2000 Sep; 14(13):1887-97. PubMed ID: 10997391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease.
    Mezzaroma I; Carlesimo M; Pinter E; Alario C; Sacco G; Muratori DS; Bernardi ML; Paganelli R; Aiuti F
    AIDS; 1999 Jul; 13(10):1187-93. PubMed ID: 10416521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
    Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
    AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level.
    Viard JP; Burgard M; Hubert JB; Aaron L; Rabian C; Pertuiset N; Lourenço M; Rothschild C; Rouzioux C
    AIDS; 2004 Jan; 18(1):45-9. PubMed ID: 15090828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.
    Shelburne SA; Visnegarwala F; Darcourt J; Graviss EA; Giordano TP; White AC; Hamill RJ
    AIDS; 2005 Mar; 19(4):399-406. PubMed ID: 15750393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Innate immunity restoration in patients with HIV/AIDS infection associated with antiretroviral therapy].
    Afani A; Jiusán L; Raby P; Sitia G; Puente J; Sepúlveda C; Miranda D; Cabrera R; Guidotti L; Lanza P
    Rev Med Chil; 2006 Jun; 134(6):689-96. PubMed ID: 17130942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opportunistic infections occurring during highly active antiretroviral treatment.
    Michelet C; Arvieux C; François C; Besnier JM; Rogez JP; Breux JP; Souala F; Allavena C; Raffi F; Garre M; Cartier F
    AIDS; 1998 Oct; 12(14):1815-22. PubMed ID: 9792382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients.
    Revankar SG; Sanche SE; Dib OP; Caceres M; Patterson TF
    AIDS; 1998 Dec; 12(18):2511-3. PubMed ID: 9875598
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study.
    Nicolatou-Galitis O; Velegraki A; Paikos S; Economopoulou P; Stefaniotis T; Papanikolaou IS; Kordossis T
    Oral Dis; 2004 May; 10(3):145-50. PubMed ID: 15089923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.
    Watson DC; Farley JJ
    Pediatr Infect Dis J; 1999 Aug; 18(8):682-9. PubMed ID: 10462336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.